Q2 FY2026 EarningsQ2 FY2026 beat revenue consensus with $51.2M vs. $49.7M expected, driven by 92% YoY growth in ANKTIVA® sales. While Loss from Operations of -$61.7M was narrower than the expected -$66.6M, GAAP EPS missed significantly at -$0.22 vs. -$0.09 expected due to a $140.8M non-cash fair value adjustment on liabilities. Normalized Net Loss of -$81.0M also trailed the -$66.9M consensus, reflecting higher-than-expected R&D and SG&A investment to support commercial scaling.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: ImmunityBio(IBRX) the Revenue is 51.24 M (+93.91%), Beat estimate;the EBIT is -61.7 M (+13.45%), Beat estimate;the EPS is -0.22 (-120%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.05B93.91%
0.05B88.07%
+0.00B5.84%
EBITExceed expectations
-0.06B13.45%
-0.07B6.64%
+0.00B6.81%
EPSMiss expectations
-0.22120.00%
-0.0910.00%
-0.1300130.00%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf